Healthcare industry

Article - 19/03/2018

Regenerative medicine: curing rather than simply treating diseases

Some scientists refer to the latest developments in the field of regenerative medicine as the "next revolution in medicine". With the help of gene therapies or stem cells, regenerative medicine aims not only to treat disease symptoms, but to cure them at source. Some approaches are already being used to treat patients and several others are close to application.

Big Data - 13/03/2018

“More data does not automatically imply more knowledge“

In Germany, one of the big names in evidence-based medicine is Prof. Dr. rer. nat. Gerd Antes, co-director of Cochrane Germany. In the following interview, Antes talks about the hype surrounding big data, warns against false promises and reminds us about what is taken for granted.

Article - 21/02/2018

HepaRegeniX – a start-up is taking it up a step!

HepaRegeniX, a biotech company founded in 2016, specialises in developing drugs that restore the regenerative capacity of diseased livers. The three founders of the biotech start-up, Prof. Dr. Lars Zender, Prof. Dr. Stefan Laufer and Dr. Wolfgang Albrecht, anticipate starting clinical testing of the first drug candidate in 2019.

Article - 18/01/2018

Medications that target metastasing tumours

Tumour metastases are often resistant to the drug that is used to eliminate the primary tumour. Genome-wide analyses of mutation patterns in the primary tumour and its metastases provide information on the aggressiveness of cancer and may help to find the best available means of further treatment. This has been demonstrated by scientists from Heidelberg in a clinical trial on the molecular evolution of renal cancer.

CureVac AG, a leading clinical-stage biopharmaceutical company focused on the development of pioneering mRNA therapeutics, and Arcturus Therapeutics Ltd. (NASDAQ:ARCT), an RNA medicines company, today announced they have entered into a broad strategic collaboration to jointly discover, develop and commercialize novel messenger RNA (mRNA) therapeutics.

Big Data - 14/12/2017

Looking at the whole genome raises new questions

Research laboratories around the world have long focused on studying the whole human genome. It is hoped that knowing the whole human genome will improve diagnostics and enable more specific therapies. Although genome analysis has not yet reached routine clinical application, whole genome sequencing has already raised many ethical and legal issues - for researchers, physicians and patients.

Tuebingen, Germany and Houston, Texas, October 4, 2017 – Immatics, a leading company in the field of cancer immunotherapy, today announced the completion of its Series E financing, raising $58 million.

Company profile - 04/09/2017

Mireca: a new drug for stopping the progression of eye diseases

A team of researchers from several EU countries has developed a new drug that stops the progression of hereditary retinal diseases. The project partners founded a company called Mireca Medicines GmbH in the city of Tübingen to bring the drug to market.

Article - 24/07/2017

Cancer medicine development as a science and industry partnership

The German Cancer Research Center (DKFZ) and Bayer AG are collaborating on a strategic partnership focusing on the development of innovative cancer therapies. The two partners have developed an active substance which selectively blocks a mutation of a metabolic enzyme that occurs in certain types of cancer. The substance has been successfully tested in preclinical studies and is now also being tested in a clinical trial on patients with brain…

Article - 04/07/2017

Ruxolitinib – successful graft-versus-host disease treatment

Graft-versus-host disease is a serious complication in leukaemia patients who have been given a blood stem cell transplant from a genetically different person. Prof. Dr. Nikolas von Bubnoff and Prof. Dr. Robert Zeiser from the Department of Haematology, Oncology and Stem Cell Transplantation at Freiburg University Medical Centre initiated a Germany-wide study to show that an active substance called ruxolitinib has a promising therapeutic effect.…

Article - 26/06/2017

Hope for mRNA vaccines despite damper

The pressure is on to develop novel vaccines based on messenger RNA and aimed at combating cancer and protecting against pandemics. Although mRNA vaccination as a cancer monotherapy has suffered a setback this year, the industry is nevertheless confident that it will succeed because of existing proof that mRNA vaccines stimulate the body's immune defence.

Article - 31/05/2017

Peritoneal cancer – long-term survival with good quality of life

Thanks to an innovative treatment procedure that has been in use since 2005, surgeons from Tübingen University Hospital have been able to prolong the survival of patients with peritoneal cancer and give them a higher quality of life. This is done using a technique based on complex surgery followed by immediate intraoperative local chemotherapy on the peritoneum.

Article - 24/05/2017

Ralf Reski: from moss to humans

Prof. Dr. Ralf Reski conducts basic research at the University of Freiburg. But this is not all the well-known plant biotechnologist does. He also wants his ideas to become concrete products. This is why he established Greenovation Biotech GmbH, a company which produces novel drugs in mosses. The company’s first moss-produced drug candidate – Moss-aGal – a recombinant form of human α-galactosidase, is now being tested in a phase I clinical trial.…

TolerogenixX GmbH has developed a patented and clinically tested cell therapy technique for individualised immunosuppression in transplant patients. The technique enables the targeted disabling of undesired reactions caused by the immune system’s defences. As a seed stage investor, High-Tech Gründerfonds (HTGF) will finance this innovative technique and the preparations for Phase II of the clinical trial, which begins in spring 2018. Further…

Personalised Medicine - 04/05/2017

Big data make therapy work better

An international team of researchers has shown for acute myeloid leukaemia (AML) that cancer therapy can be personalised using big data. The authors of the study “believe this paper is a step towards validation of genetic techniques as a route to personalised medicine”.

Article - 20/04/2017

Health app to be integrated into clinical trials

Questionnaires are a thing of the past, now it is becoming increasingly likely that information for clinical trials will be collected via apps in the future. A new research platform has been developed to prepare patient data transmitted via smartphone applications. Doctors who are carrying out research will thus have access to more accurate results that will also ultimately benefit patients.

Press release - 06/04/2017

Start-up in the garage – a location with prospects

Newly established start-up wins award – Mireca Medicines GmbH develops treatment for hereditary eye disease and receives Innovation Award of the biotechnology regions in Germany

The Commission welcomes the adoption of its proposal for two Regulations on medical devices which establish a modernised and more robust EU legislative framework to ensure better protection of public health and patient safety.

Article - 07/03/2017

KiTZ: Hopp Children’s Tumour Center at NCT Heidelberg

The Heidelberg University Hospital and the DKFZ have established the "Hopp Children's Tumor Center at NCT Heidelberg" (KiTZ) where doctors, scientists, nursing staff and other specialists work side by side on new diagnostic and therapeutic options to help children with cancer.

Article - 26/01/2017

Clinical cancer registration to improve patient treatment and care

Germany records around 500,000 new cases of cancer every year. The number is steadily growing, mainly due to an ageing population that leads to an increased risk of cancer. The German government is planning to establish clinical cancer registries in all German states so that all cancer patients receive the best possible treatment. In Baden-Württemberg, all new cancer cases are already recorded. However, the data are still not as comprehensive as…

Dossier - 17/01/2017

Phytopharmaceuticals – fighting disease with natural substances

Phytopharmaceuticals are herbal medicines whose efficacy is down to one or several plant substances or active ingredients. They have been used for treating diseases since time immemorial. This traditional knowledge is still the basis for many medicinal products made from plants or parts thereof. Herbal medicines have been produced in Baden-Württemberg for many generations.

HepaRegeniX GmbH, a new Biotech company developing innovative treatments for liver diseases, announced today the completion of a €9 million Series A financing. The round was led by Boehringer Ingelheim Venture Fund GmbH (BIVF) and Novo Seeds, and complemented by the High-Tech Gruenderfonds and coparion.

Article - 13/12/2016

Smart sensor technology from Ulm can do more than just breath analysis

Detecting disease-specific molecules in human breath is technically feasible, but time-consuming and rather costly. "µbreath" could soon change this. The breath gas analysis device has all the necessary requirements for commercial success in the healthcare sector: it is compact, accurate, highly sensitive and fast. The chemist who developed µbreath, Prof. Boris Mizaikoff from Ulm University, and his partners are hoping to start…